Literature DB >> 4008629

Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine.

M L Clements, E L Tierney, B R Murphy.   

Abstract

The infectivity and immunogenicity of live attenuated A/Washington/897/80 cold-adapted reassortant virus vaccine was evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:4) and seropositive (hemagglutination inhibition titer, greater than 1:4) adult volunteers. The vaccine was efficient in infecting seronegative volunteers (94%). Moreover, 51% of seropositive vaccinees were infected by the virus. After live virus vaccination, greater than 83% of both seronegative and seropositive vaccinees achieved a level of nasal wash antibody previously associated with resistance to infection with influenza A virus. These findings indicate that both seronegative and seropositive vaccinees can benefit from live virus vaccination.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4008629      PMCID： PMC271838          DOI： 10.1128/jcm.21.6.997-999.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Trials of Live Influenza Vaccine in the Royal Air Force.

Authors:  J C McDonald; A J Zuckerman; A S Beare; D A Tyrrell
Journal:  Br Med J       Date:  1962-04-14

2.  Live, attenuated influenza A/England/42/72 (H3N2) virus vaccine: a field trial.

Authors:  R J Rubin; G R Noble; L Corey; W J Brown; D Brandling-Bennett; H S Kaye; M T Coleman; M B Gregg; W R Dowdle
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Summary of clinical trials of inactivated influenza vaccine - 1978.

Authors:  J R La Montagne; G R Noble; G V Quinnan; G T Curlin; W C Blackwelder; J I Smith; F A Ennis; F M Bozeman
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

4.  Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers.

Authors:  M L Clements; R F Betts; H F Maassab; B R Murphy
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

5.  Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers.

Authors:  B R Murphy; M L Clements; H P Madore; J Steinberg; S O'Donnell; R Betts; D Demico; R C Reichman; R Dolin; H F Maassab
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

6.  Cold-adapted recombinant influenza A virus vaccines in seronegative young children.

Authors:  P F Wright; N Okabe; K T McKee; H F Maassab; D T Karzon
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

7.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

8.  Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.

Authors:  M L Clements; S O'Donnell; M M Levine; R M Chanock; B R Murphy
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection.

Authors:  M L Clements; R F Betts; B R Murphy
Journal:  Lancet       Date:  1984-03-31       Impact factor: 79.321

10.  Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.

Authors:  F Y Liew; S M Russell; G Appleyard; C M Brand; J Beale
Journal:  Eur J Immunol       Date:  1984-04       Impact factor: 5.532
View more
  4 in total

1.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.

Authors:  J J Treanor; F K Roth; R F Betts
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.

Authors:  Zhongying Chen; Lomi Kim; Kanta Subbarao; Hong Jin
Journal:  Vaccine       Date:  2012-02-11       Impact factor: 3.641

4.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.